The oral semaglutide results were slightly better than what appeared in the PIONEER trials (1.8% average reduction versus 1.1%), while the injectable results were comparable to the SUSTAIN trials (1.4% versus 1.56%).[1] The weight loss results from this real-world study were somewhat better than clinical trials, which researchers attribute to the higher baseline weight in their patient population (average 106.9 kg versus 88-92 kg in trials) and concurrent use of other medications that contribute to weight loss.[1] Study Strengths and Limitations The study's main strength is that it reflects actual clinical practice
essencial investir em prticas de produo seguras, controles de qualidade rigorosos, educao alimentar e monitoramento contnuo para mitigar os riscos associados insegurana de alimentos
Additional priming beyond the first droplet wastes medication and can alter the actual dose you receive, making dose tracking unreliable
doi: 10.1056/NEJMoa2206038 [DOI] [PubMed] [Google Scholar] 195.Pi-Sunyer X, Astrup A, Fujioka K, et al
F., Lingvay, I., & STEP1 Investigators
